2023-509257-31-00CompletedPhase 1
Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer’s Disease (AD)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 6 Mar 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- First submitted
- 16 Jul 2024
- Start date
- 12 Feb 2025
- Lead sponsor
- Ionis Pharmaceuticals Inc.
- Diseases
- Alzheimer disease
- EU CT number
- 2023-509257-31-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 7
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital de la Santa Creu i Sant Pau | Barcelona | Spain | Completed |
| Fundacion CITA Alzheimer | Donostia | Spain | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.